Travere Therapeutics, Inc.
TVTX
주식 순위
#3499
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies... Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only FDA-approved medicine for FSGS. The company also markets Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder causing recurring kidney stones. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). Formerly Retrophin, Inc. (renamed November 2020), Travere is headquartered in San Diego, California, and incorporated in Delaware.
주가
$52.43
마지막 동기화: 2026-10-20
시가총액
$4.94B
변동 (1일)
3.83%
변동 (1년)
88.58%
국가
US
거래 Travere Therapeutics, Inc. (TVTX)
카테고리
Healthcare
Travere Therapeutics, Inc. (TVTX)의 매출
Jun 2026 기준 매출 TTM: $591.33M
Travere Therapeutics, Inc.의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 $591.33M입니다. 2023년에 회사는 $145.24M의 수익을 올렸으며 이는 2022년의 $109.46M 대비 증가입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
Travere Therapeutics, Inc.의 수익 기록 (2009 ~ 2026)
매년 말 매출
| 연도 | 매출 | 변화 |
|---|---|---|
| 2026 (TTM) | $591.33M | 153.60% |
| 2024 | $233.18M | 60.55% |
| 2023 | $145.24M | 32.69% |
| 2022 | $109.46M | -16.97% |
| 2021 | $131.84M | -33.52% |
| 2020 | $198.32M | 13.11% |
| 2019 | $175.34M | 6.75% |
| 2018 | $164.25M | 6.01% |
| 2017 | $154.94M | 15.98% |
| 2016 | $133.59M | 33.74% |
| 2015 | $99.89M | 254.19% |
| 2014 | $28.20M | 0.00% |
| 2013 | 0.00 | 0.00% |
| 2012 | 0.00 | 0.00% |
| 2009 | 0.00 | 0.00% |
유사 기업 또는 경쟁사의 매출
| 회사 | 매출 | 매출 차이 | 국가 |
|---|---|---|---|
| $12.62B | 2,034.90% |
US
|
|
| $2.23B | 276.78% |
US
|
|
| $15.74B | 2,562.52% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 918.26% |
NL
|
